Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ('Gain”, or the 'Company”), a clinical-stage biotechnology company leading the ...

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global ...

Detailed price information for Northrop Grumman Corp (NOC-N) from The Globe and Mail including charting and trades.

Fintel reports that on July 23, 2025, BTIG downgraded their outlook for Unity Software (NYSE:U) from Neutral to Sell. Analyst ...

BTIG analyst Andre Madrid raised the firm’s price target on Northrop Grumman (NOC) to $630 from $575 and keeps a Buy rating on the shares.

Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain ...

BTIG’s Tim Chiang believes the company is steadily progressing with these key programs. The analyst said, “We believe SRPT is making progress on the gene therapy manufacturing front, ...